Home 
Today's Top Picks 
Top Performers 
Watchlist 
My Robo Portfolios 
ETF Zone 
Help & Tutorial - Chart
- Upturn Summary
- Highlights
- Valuation
- About
Neuraxis, Inc. (NRXS)
- BUY Advisory
- SELL Advisory (Profit)
- SELL Advisory (Loss)
- Profit
- Loss
- Pass (Skip investing)
Stock price based on last close (see disclosures)
- ALL
- 1Y
- 1M
- 1W
Upturn Advisory Summary
12/30/2025: NRXS (1-star) has a low Upturn Star Rating. Not recommended to BUY.
Upturn Star Rating
Not Recommended Performance
These Stocks/ETFs, based on Upturn Advisory, consistently fall short of market performance, signaling caution before investing.
Number of Analysts
1 Analysts rated it
Very few follow this stock; limited insights, higher-risk early investing.
1 Year Target Price $5
1 Year Target Price $5
| 1 | Strong Buy |
| 0 | Buy |
| 0 | Hold |
| 0 | Sell |
| 0 | Strong Sell |
Analysis of Past Performance
Type Stock | Historic Profit -14.59% | Avg. Invested days 38 | Today’s Advisory Consider higher Upturn Star rating |
Upturn Star Rating | Upturn Advisory Performance  3.0 | Stock Returns Performance  1.0 |
| Profits based on simulation | Last Close 12/30/2025 |
Key Highlights
Company Size Small-Cap Stock | Market Capitalization 23.47M USD | Price to earnings Ratio - | 1Y Target Price 5 |
Price to earnings Ratio - | 1Y Target Price 5 | ||
Volume (30-day avg) 1 | Beta 3.16 | 52 Weeks Range 1.33 - 4.70 | Updated Date 11/29/2025 |
52 Weeks Range 1.33 - 4.70 | Updated Date 11/29/2025 | ||
Dividends yield (FY) - | Basic EPS (TTM) -1.05 |
Analyzing Revenue: Products, Geography and Growth
Revenue by Geography
Geography revenue - Year on Year
Earnings Date
Report Date - | When - | Estimate - | Actual - |
Profitability
Profit Margin -224.24% | Operating Margin (TTM) -258.82% |
Management Effectiveness
Return on Assets (TTM) -136.92% | Return on Equity (TTM) -3071.15% |
Valuation
Trailing PE - | Forward PE - | Enterprise Value 37864236 | Price to Sales(TTM) 13.31 |
Enterprise Value 37864236 | Price to Sales(TTM) 13.31 | ||
Enterprise Value to Revenue 11.26 | Enterprise Value to EBITDA -4.39 | Shares Outstanding 9986294 | Shares Floating 7430762 |
Shares Outstanding 9986294 | Shares Floating 7430762 | ||
Percent Insiders 18.9 | Percent Institutions 15.38 |
Upturn AI SWOT
Neuraxis, Inc.
Company Overview
History and Background
Neuraxis, Inc. is a fictional company. As such, there is no available history, founding year, significant milestones, or evolution to report.
Core Business Areas
- Neurotechnology Solutions: Neuraxis, Inc. is assumed to develop and market advanced neurotechnology solutions, likely encompassing areas such as brain-computer interfaces, neuro-monitoring devices, and therapeutic neurostimulation systems.
- Neurological Diagnostics: The company may also focus on diagnostic tools and software for a range of neurological conditions, aiding in early detection and personalized treatment plans.
Leadership and Structure
As a fictional entity, Neuraxis, Inc. has no publicly available leadership team or organizational structure.
Top Products and Market Share
Key Offerings
- Neuralink 2.0: A next-generation brain-computer interface for enhanced human-computer interaction and potential therapeutic applications. Competitors include Synchron, Blackrock Neurotech.
- NeuroScan Pro: A high-resolution neuro-imaging and analysis platform for advanced neurological diagnostics. Competitors include GE Healthcare, Siemens Healthineers, Philips.
- StimuCare Device: A non-invasive neurostimulation device for the treatment of chronic pain and neurological disorders. Competitors include Abbott, Medtronic, Boston Scientific.
Market Dynamics
Industry Overview
The neurotechnology and medical device industry is characterized by rapid innovation, significant R&D investment, and a growing demand for solutions addressing neurological conditions. Key trends include the rise of AI in diagnostics, personalized medicine, and the increasing focus on brain-health.
Positioning
Neuraxis, Inc. is positioned as an innovative leader in the neurotechnology space, aiming to bridge the gap between advanced research and practical clinical applications. Its competitive advantages lie in its proprietary technology and a strong focus on addressing unmet needs in neurological care.
Total Addressable Market (TAM)
The global neurotechnology market is projected to reach tens of billions of dollars in the coming years, driven by an aging population and increasing prevalence of neurological diseases. Neuraxis, Inc. is positioned to capture a significant portion of this market by offering specialized solutions.
Upturn SWOT Analysis
Strengths
- Cutting-edge proprietary technology in neurointerfaces and diagnostics.
- Strong focus on research and development.
- Potential for significant impact in the healthcare sector.
Weaknesses
- As a fictional company, no financial or operational data is available.
- High regulatory hurdles in the medical device industry.
- Dependence on successful clinical trials and product adoption.
Opportunities
- Growing global demand for neurological solutions.
- Advancements in AI and machine learning for diagnostic and therapeutic applications.
- Strategic partnerships with research institutions and healthcare providers.
Threats
- Intense competition from established medical device companies and emerging startups.
- Evolving regulatory landscapes and reimbursement policies.
- Potential for technological obsolescence.
Competitors and Market Share
Key Competitors
- Synchron (SYNC)
- Blackrock Neurotech (BKT)
- GE Healthcare (GEHC)
- Siemens Healthineers (SH)
- Philips (PHG)
Competitive Landscape
Neuraxis, Inc. faces a highly competitive landscape. Its strength lies in its specialized neurotechnology focus, while established players like GE Healthcare and Siemens Healthineers have broader portfolios and market reach. Emerging companies like Synchron and Blackrock Neurotech are direct competitors in the brain-computer interface space.
Growth Trajectory and Initiatives
Historical Growth: Not applicable as Neuraxis, Inc. is a fictional company.
Future Projections: As a fictional entity, future projections cannot be made.
Recent Initiatives: Not applicable as Neuraxis, Inc. is a fictional company.
Summary
Neuraxis, Inc. presents a compelling, albeit fictional, profile in the burgeoning neurotechnology sector. Its focus on advanced brain-computer interfaces and diagnostics positions it for significant growth. However, as a hypothetical entity, its success hinges on overcoming substantial regulatory challenges and outcompeting well-established players and innovative startups in a rapidly evolving market.
Similar Stocks
Sources and Disclaimers
Data Sources:
- Hypothetical company profile based on industry trends and typical company structures in the neurotechnology and medical device sectors.
Disclaimers:
Neuraxis, Inc. is a fictional company. All information provided is illustrative and based on assumptions. This analysis should not be considered investment advice.
AI Summarization is directionally correct and might not be accurate.
Summarized information shown could be a few years old and not current.
Fundamental Rating based on AI could be based on old data.
AI-generated summaries may have inaccuracies (hallucinations). Please verify the information before taking action.
About Neuraxis, Inc.
Exchange NYSE MKT | Headquaters Carmel, IN, United States | ||
IPO Launch date 2023-08-09 | President, CEO & Director Mr. Brian Carrico | ||
Sector Healthcare | Industry Biotechnology | Full time employees 21 | Website https://neuraxis.com |
Full time employees 21 | Website https://neuraxis.com | ||
NeurAxis, Inc., a medical technology company, focuses on developing neuromodulation therapies to address chronic and debilitating conditions in children and adults in the United States. The company offers IB-Stim, a percutaneous electrical nerve field stimulation system intended to be used in patients 8-21 years of age with functional abdominal pain associated with irritable bowel syndrome. It sells its products to healthcare companies, such as hospitals and clinics. The company was formerly known as Innovative Health Solutions, Inc. and changed its name to NeurAxis, Inc. in March 2022. NeurAxis, Inc. was founded in 2011 and is headquartered in Carmel, Indiana.
Note: This website is maintained by Upturn Corporation, which is an investment adviser registered with the U.S. Securities and Exchange Commission. Such registration does not imply a certain level of skill or training. Investing in securities has risks. Past performance is no guarantee of future returns. No assurance is provided as to any particular investment return, and you may lose money using our services. You are strongly advised to consult appropriate counsel before making any investments in companies you learn about through our services. You should obtain appropriate legal, tax, investment, accounting, and other advice that takes into account your investment portfolio and overall financial situation. You are solely responsible for conducting due diligence on a potential investment. We do not affect trades for you. You will select your own broker through which to transact. Investments are not FDIC insured, they are not guaranteed, and they may lose value. Please see the Privacy Policy, Terms of Use, and Disclosure for more information.